semaglutide and tirzepatide for weight loss vs GLP-1 Medications for Weight Loss:

Phase 1b studies in patients with type 2 diabetes demonstrated proof-of-concept efficacy, with dose-dependent reductions in fasting plasma glucose and postprandial glucose excursions over 28 days of treatment

This modification led to an almost complete conversion to the target peptide, achieving excellent purity and a high yield

PlexusDx offers tirzepatide injection (a dual GLP-1/GIP agonist) at $289/mo month-to-month, or from $249/mo on the 6-month plan, or the GLP-Squared Injection combining both compounds for enhanced pathway engagement

People with cardiovascular concerns or high blood pressure need careful screening before using it

Maintenance dosing is typically appropriate when a patient has reached targeted clinical or individual weight loss goals and approached a plateau point where there is no active weight loss or weight regain, says Gitanjali Srivastava, MD, medical director of Vanderbilt Obesity Medicine